BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease

Reuters

03 Apr

BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease

April 3 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:

ALDEYRA THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE REPROXALAP NEW DRUG APPLICATION FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE
ALDEYRA THERAPEUTICS INC -NEW DRUG APPLICATION RESUBMISSION EXPECTED MID-YEAR 2025
ALDEYRA THERAPEUTICS INC -TOP-LINE DATA FROM DRY EYE CHAMBER TRIAL AND FIELD TRIAL EXPECTED IN Q2 2025
ALDEYRA THERAPEUTICS - LETTER IDENTIFIED CONCERNS WITH DATA FROM TRIAL SUBMITTED TO NDA THAT MAY HAVE AFFECTED INTERPRETATION OF RESULTS

Source text: ID:nBw4Hk80Pa

Further company coverage: ALDX.O

(((( Reuters.briefs@thomsonreuters.com ;));))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2524625614"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524625614\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524625614?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-03 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524625614","market":"nz","top_or_hot":-1,"title":"BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease</title></head><body><p><span>April 3 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ALDX\">Aldeyra Therapeutics Inc</a> <span>ALDX.O</span>:</p><ul><li><p>ALDEYRA THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE REPROXALAP NEW DRUG APPLICATION FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE</p></li><li><p>ALDEYRA THERAPEUTICS INC -NEW DRUG APPLICATION RESUBMISSION EXPECTED MID-YEAR 2025</p></li><li><p>ALDEYRA THERAPEUTICS INC -TOP-LINE DATA FROM DRY EYE CHAMBER TRIAL AND FIELD TRIAL EXPECTED IN Q2 2025</p></li><li><p>ALDEYRA THERAPEUTICS - LETTER IDENTIFIED CONCERNS WITH DATA FROM TRIAL SUBMITTED TO NDA THAT MAY HAVE AFFECTED INTERPRETATION OF RESULTS</p></li></ul><p>Source text: <span>ID:nBw4Hk80Pa</span></p><p>Further company coverage: <span>ALDX.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-03 20:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye Disease</title></head><body><p><span>April 3 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ALDX\">Aldeyra Therapeutics Inc</a> <span>ALDX.O</span>:</p><ul><li><p>ALDEYRA THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE REPROXALAP NEW DRUG APPLICATION FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE</p></li><li><p>ALDEYRA THERAPEUTICS INC -NEW DRUG APPLICATION RESUBMISSION EXPECTED MID-YEAR 2025</p></li><li><p>ALDEYRA THERAPEUTICS INC -TOP-LINE DATA FROM DRY EYE CHAMBER TRIAL AND FIELD TRIAL EXPECTED IN Q2 2025</p></li><li><p>ALDEYRA THERAPEUTICS - LETTER IDENTIFIED CONCERNS WITH DATA FROM TRIAL SUBMITTED TO NDA THAT MAY HAVE AFFECTED INTERPRETATION OF RESULTS</p></li></ul><p>Source text: <span>ID:nBw4Hk80Pa</span></p><p>Further company coverage: <span>ALDX.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH0K9:1","article_id":"2524625614","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524625614","pubTimestamp":1743682393,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye DiseaseApril 3 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:ALDEYRA THE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ALDX":"Aldeyra Therapeutics Inc"},"translate_title":"BRIEF-Aldeyra收到FDA关于Reproxalap治疗干眼症新药申请的完整回复函","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALDX":0.9},"content_text":"BRIEF-Aldeyra Receives Complete Response Letter From The FDA For The Reproxalap New Drug Application For The Treatment Of Dry Eye DiseaseApril 3 (Reuters) - Aldeyra Therapeutics Inc ALDX.O:ALDEYRA THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR THE REPROXALAP NEW DRUG APPLICATION FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASEALDEYRA THERAPEUTICS INC -NEW DRUG APPLICATION RESUBMISSION EXPECTED MID-YEAR 2025ALDEYRA THERAPEUTICS INC -TOP-LINE DATA FROM DRY EYE CHAMBER TRIAL AND FIELD TRIAL EXPECTED IN Q2 2025ALDEYRA THERAPEUTICS - LETTER IDENTIFIED CONCERNS WITH DATA FROM TRIAL SUBMITTED TO NDA THAT MAY HAVE AFFECTED INTERPRETATION OF RESULTSSource text: ID:nBw4Hk80PaFurther company coverage: ALDX.O (((( Reuters.briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}